Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
- 6 March 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 68 (10), 797
- https://doi.org/10.1212/01.wnl.0000259143.52138.5c
Abstract
The only action ascribed to TBZ in achieving the clinical benefit was inhibiting presynaptic vesicular monoamine transporters to block amine reuptake and secondarily decrease dopamine levels. Although this mechanism is clearly established, TBZ is also functionally effective as a dopamine receptor antagonist based on a large body of rigorous literature. This additional mechanism could well contribute to the clinical benefit observed and possibly explain some unexpected results.Keywords
This publication has 6 references indexed in Scilit:
- Tetrabenazine as antichorea therapy in Huntington diseaseNeurology, 2006
- In vivo measures of dopaminergic radioligands in the rat brain: Equilibrium infusion studiesSynapse, 2001
- Concentration–Effect Relationships of Tetrabenazine and Dihydrotetrabenazine in the RatJournal of Pharmaceutical Sciences, 1987
- Tetrabenazine induces acute dystonic reactionsAnnals of Neurology, 1985
- Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine.Proceedings of the National Academy of Sciences of the United States of America, 1983
- Tetrabenazine has properties of a dopamine receptor antagonistAnnals of Neurology, 1982